Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation

European Journal of Immunology

Volumn 38, Issue 9, 2008, Pages 2401-2411

  Fissolo, Nicolas ^a   Kraus, Marianne ^a   Reich, Michael ^a   Ayturan, Miriam ^a   Overkleeft, Herman ^b   Driessen, Christoph ^a   Weissert, Robert ^a,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b LEIDEN UNIVERSITY   (Netherlands)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Antigen presentation; MHC; NF B; Proteasome; T cell

Indexed keywords

BORTEZOMIB; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEASOME; PROTEINASE; PROTEINASE INHIBITOR; BORONIC ACID DERIVATIVE; CATHEPSIN; CATHEPSIN S; DIPEPTIDE; GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35 55); MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35-55); N MORPHOLINOUREA LEUCINE HOMOPHENYLALANINE PHENYL VINYLSULFONE; N-MORPHOLINOUREA-LEUCINE-HOMOPHENYLALANINE-PHENYL-VINYLSULFONE; PEPTIDE FRAGMENT; PYRAZINE DERIVATIVE; SULFONE;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL ISOLATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DEGENERATION; DRUG EFFICACY; ENCEPHALOMYELITIS; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GEL MOBILITY SHIFT ASSAY; IN VIVO STUDY; LYMPHOID ORGAN; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN DEGRADATION; T LYMPHOCYTE; ALLERGIC ENCEPHALOMYELITIS; ANIMAL; BRAIN; C57BL MOUSE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY; GLIA; IMMUNOLOGY; LYMPHOID TISSUE; LYSOSOME; METABOLISM; NERVE CELL; RAT;

ANIMALS; BORONIC ACIDS; BRAIN; CATHEPSINS; DIPEPTIDES; DRUG THERAPY, COMBINATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GLYCOPROTEINS; LYMPHOID TISSUE; LYSOSOMES; MICE; MICE, INBRED C57BL; NEUROGLIA; NEURONS; NF-KAPPA B; PEPTIDE FRAGMENTS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RATS; SULFONES; T-LYMPHOCYTES;

EID: 55249102985     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200838413     Document Type: Article

References (41)

1. Lassmann, H., Classification of demyelinating diseases at the interface between etiology and pathogenesis. Curr. Opin. Neurol. 2001. 14: 253-258.
2. Wekerle, H., Kojima, K., Lannes-Vieira, J., Lassmann, H. and Linington, C., Animal models. Ann. Neurol. 1994. 36(Suppl.): S47-S53.
3. Kuchroo, V. K., Anderson, A. C., Waldner, H., Munder, M., Bettelli, E. and Nicholson, L. B., T cell response in experimental autoimmune encephalomyelitis (EAE): Role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu. Rev. Immunol. 2002. 20: 101-123.
4. Villadangos, J. A. and Ploegh, H. L., Proteolysis in MHC class II antigen presentation: Who's in charge? Immunity 2000. 12: 233-239.
5. Palmer, J. T., Rasnick, D., Klaus, J. L. and Bromme, D., Vinyl sulfones as mechanism-based cysteine protease inhibitors. J. Med. Chem. 1995. 38: 3193-3196.
6. Allen, E. M., Vitali, N., Underwood, S., Sweeney, D., Wheeler, D., Lawrence, C., Patterson, J., Graupe, M. et al., Reversible cathepsin S (CATS) inhibitors block invariant chain degradation both in vitro and in vivo. Inflamm. Res. 2001. 50(Suppl. 3): 159.
7. Fiebiger, E., Meraner, P., Weber, E., Fang, I. F., Stingl, G., Ploegh, H. and Maurer, D., Cytokines regulate proteolysis in major histocompatibility complex class II-dependent antigen presentation by dendritic cells. J. Exp. Med. 2001. 193: 881-892.
8. Podolin, P. L., Capper, E. A., Bolognese, B. J., Chalupowicz, D. C., Dong, X., Fox, J. H., Gao, E. N. et al., Inhibition of cathepsin S block invariant chain processing and antigen-induced arthritis in vivo. Inflamm. Res. 2001. 50(Suppl. 3): 159.
9. Riese, R. J., Wolf, P. R., Bromme, D., Natkin, L. R., Villadangos, J. A., Ploegh, H. L. and Chapman, H. A., Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 1996. 4: 357-366.
10. Villadangos, J. A., Riese, R. J., Peters, C., Chapman, H. A. and Ploegh, H. L., Degradation of mouse invariant chain: Roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. J. Exp. Med. 1997. 186: 549-560.
11. Glickman, M. H. and Ciechanover, A., The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol. Rev. 2002. 82: 373-428.
12. Kessler, B. M., Tortorella, D., Altun, M., Kisselev, A. F., Fiebiger, E., Hekking, B. G., Ploegh, H. L. and Overkleeft, H. S., Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits. Chem. Biol. 2001. 8: 913-929.
13. Tak, P. P. and Firestein, G. S., NF-kappaB: A key role in inflammatory diseases. J. Clin. Invest. 2001. 107: 7-11.
14. Kaltschmidt, B., Baeuerle, P. A. and Kaltschmidt, C., Potential involvement of the transcription factor NF-kappa B in neurological disorders. Mol. Aspects Med. 1993. 14: 171-190.
15. Pahan, K., Raymond, J. R. and Singh, I., Inhibition of phosphatidylinositol 3-kinase induces nitric-oxide synthase in lipopolysaccharide- or cytokine-stimulated C6 glial cells. J. Biol. Chem. 1999. 274: 7528-7536.
16. Pahan, K., Sheikh, F. G., Namboodiri, A. M. and Singh, I., Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. 1997. 100: 2671-2679.
17. Baldwin, Jr A. S. The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu. Rev. Immunol. 1996. 14: 649-683.
18. Thanos, D. and Maniatis, T., NF-kappa B: A lesson in family values. Cell 1995. 80: 529-532.
19. Adams, J., The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004. 5: 417-421.
20. Boccadoro, M., Morgan, G. and Cavenagh, J., Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 2005. 5: 18.
21. Ciechanover, A., The ubiquitin-proteasome pathway: On protein death and cell life. EMBO. J. 1998. 17: 7151-7160.
22. Coux, O., Tanaka, K. and Goldberg, A. L., Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 1996. 65: 801-847.
23. Nencioni, A., Grunebach, F., Patrone, F., Ballestrero, A. and Brossart, P., Proteasome inhibitors: Antitumor effects and beyond. Leukemia 2007. 21: 30-36.
24. Elliott, P. J., Zollner, T. M. and Boehncke, W. H., Proteasome inhibition: A new anti-inflammatory strategy. J. Mol. Med. 2003. 81: 235-245.
25. Palombella, V. J., Conner, E. M., Fuseler, J. W., Destree, A., Davis, J. M., Laroux, F. S., Wolf, R. E. et al., Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc. Natl. Acad. Sci. USA 1998. 95: 15671-15676.
26. Riese, R. J., Mitchell, R. N., Villadangos, J. A., Shi, G. P., Palmer, J. T., Karp, E. R., De Sanctis, G. T. et al., Cathepsin S activity regulates antigen presentation and immunity. J. Clin. Invest. 1998. 101: 2351-2363.
27. Kraus, M., Ruckrich, T., Reich, M., Gogel, J., Beck, A., Kammer, W., Berkers, C. R. et al., Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia 2007. 21: 84-92.
28. Hilliard, B., Samoilova, E. B., Liu, T. S., Rostami, A. and Chen, Y., Experimental autoimmune encephalomyelitis in NF-kappa B-deficient mice: Roles of NF-kappa B in the activation and differentiation of autoreactive T cells. J. Immunol. 1999. 163: 2937-2943.
29. Pahan, K. and Schmid, M., Activation of nuclear factor-kB in the spinal cord of experimental allergic encephalomyelitis. Neurosci. Lett. 2000. 287: 17-20.
30. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J. and Anderson, K. C., The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001. 61: 3071-3076.
31. Sunwoo, J. B., Chen, Z., Dong, G., Yeh, N., Crowl Bancroft, C., Sausville, E., Adams, J. et al., Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 2001. 7: 1419-1428.
32. Tan, C. and Waldmann, T. A., Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res. 2002. 62: 1083-1086.
33. Beck, H., Schwarz, G., Schroter, C. J., Deeg, M., Baier, D., Stevanovic, S., Weber, E. et al., Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. Eur. J. Immunol. 2001. 31: 3726-3736.
34. Nakagawa, T. Y., Brissette, W. H., Lira, P. D., Griffiths, R. J., Petrushova, N., Stock, J., McNeish, J. D. et al., Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999. 10: 207-217.
35. Barclay, J., Clark, A. K., Ganju, P., Gentry, C., Patel, S., Wotherspoon, G., Buxton, F. et al., Role of the cysteine protease cathepsin S in neuropathic hyperalgesia. Pain 2007. 130: 225-234.
36. van Loo, G., De Lorenzi, R., Schmidt, H., Huth, M., Mildner, A., Schmidt-Supprian, M., Lassmann, H. et al., Inhibition of transcription factor NFkappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat. Immunol. 2006. 7: 954-961.
37. Dantuma, N. P., Groothuis, T. A., Salomons, F. A. and Neefjes, J., A dynamic ubiquitin equilibrium couples proteasomal activity to chromatin remodeling. J. Cell. Biol. 2006. 173: 19-26.
38. Weissert, R., Wallstrom, E., Storch, M. K., Stefferl, A., Lorentzen, J., Lassmann, H., Linington, C. and Olsson, T., MHC haplotype-dependent regulation of MOG-induced EAE in rats. J. Clin. Invest. 1998. 102: 1265-1273.
39. van Swieten, P. F., Maehr, R., van den Nieuwendijk, A. M., Kessler, B. M., Reich, M., Wong, C. S., Kalbacher, H. et al., Development of an isotopecoded activity-based probe for the quantitative profiling of cysteine proteases. Bioorg. Med. Chem. Lett. 2004. 14: 3131-3134.
40. Berkers, C. R., Verdoes, M., Lichtman, E., Fiebiger, E., Kessler, B. M., Anderson, K. C., Ploegh, H. L. et al., Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat. Methods 2005. 2: 357-362.
41. Andrews, N. C. and Faller, D. V., A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 1991. 19: 2499.